杜瓦卢马布
胆道癌
吉西他滨
耐受性
顺铂
医学
肿瘤科
胆道
内科学
癌症
化疗
不利影响
无容量
免疫疗法
作者
Margherita Rimini,Lorenzo Fornaro,Mario Domenico Rizzato,Lorenzo Antonuzzo,Federico Rossari,Tomoyuki Satake,Hanne Vandeputte,Caterina Vivaldi,Tiziana Pressiani,Jessica Lucchetti,Jin Won Kim,Oluseyi Abidoye,Ilario Giovanni Rapposelli,Stefano Tamberi,Fabian Finkelmeier,Guido Giordano,Federico Nichetti,Hong Jae Chon,Chiara Braconi,Chiara Pirrone
标识
DOI：10.1016/j.ejca.2024.114199
摘要
The TOPAZ-1 phase III trial showed a survival benefit with durvalumab plus gemcitabine and cisplatin in patients with advanced biliary tract cancer (BTC). To understand this combination's real-world efficacy and tolerability, we conducted a global multicenter retrospective analysis of its first-line treatment outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI
Oracle
bc
cdercder
余味
平常的毛豆
xiahou
高大凌寒
斯寜
iNk
Li
back you up
善良的剑通
归尘
随遇而安
昏睡的蟠桃
失眠天亦
zho
laber
eee
科目三
皖公网安备34019202002308
